- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001788
Genetic Basis of Primary Immunodeficiencies
Molecular Basis of Primary Immunodeficiencies
The purpose of this study is to evaluate patients with primary immunodeficiency disorders to identify patients with mutations of the genes for the following proteins: Jak3, STAT1, STAT4, interleukin-7, interleukin-7 receptor, interleukin-12 receptor subunits, and others.
Patients will undergo screening history, physical examination, and clinical laboratory evaluation at referring institutions and tissue samples, or cell lines will be sent to the NIH. We will establish cell lines if necessary, prepare DNA and RNA for molecular genetic analysis and study cytokine signal transduction in patient cell lines.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
- INCLUSION CRITERIA:
Samples from patients with known or suspected primary immunodeficiencies, including those treated with stem cell transplants or gene correction therapy, and their families will be accepted worldwide primarily from tertiary care centers that treat patients with such immunodeficiencies.
Such patients will have documented evidence of either opportunistic infection, recurrent infection, or unusually severe responses to infectious agents that cause mild illness in unaffected individuals. In selected cases, at the discretion of the investigators, samples for testing will be obtained from consenting adult relatives of affected individuals.
Either patient-derived B cell lines or primary blood samples will be accepted although in some cases buccal swabs will also be accepted.
Blood samples may be obtained from unaffected children.
Additionally; patients with particularly interesting clinical presentations (e.g. adults with possible attenuated immunodeficiency) may be seen for outpatient visits at the NIH Clinical Center for evaluation.
Infants with SCID or other primary immunodeficiency will not be seen; their physicians will care them for and only clinical material will be sent on such patients.
Medically stable patients with mild to moderate immunodeficiency may be seen at the NIH.
We will encourage the participation of women and members of minority groups in this study.
EXCLUSION CRITERIA:
Inability to provide informed consent.
A presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
patients with primary immunodeficiency disorders
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Natural History of Immunologic Deficiency Syndrome
Time Frame: Enrollment with follow-up
|
The objectives of the study are: (1) To identify new patients with Jak3 deficiency to determine the range of mutations that occur, to study these mutations in in vitro assays and to relate these findings to the clinical presentation.
We will also try to develop improved assays for the diagnosis of Jak3 deficiency.
(2) To analyze the function of lymphoid and myeloid cells from patients who have undergone stem cell transplants for Jak3- and XSCID (3) To analyze patients with TB+SCID without mutations of Jak3 and c for mutations in IL- 7, IL-7 receptor genes.
(4) To analyze patients with defects in cell-mediated immunity to try to identify patients with mutations of the genes encoding IL-12 subunits, IL-12 receptor subunits and the transcription factors Stat1, Stat 4 and IRF.
|
Enrollment with follow-up
|
Natural History of Immunologic Deficiency Syndrome
Time Frame: Enrollment with follow-up
|
The objectives of the study are: (5) To analyze patients, including their tissues and cells, with defects in innate immunity, adaptive immunity, or both who clinically present with features suggestive of NEMO Syndrome or NEMO-like syndrome to identify individuals with mutations in IKK (NEMO), IB, and other genes that modify the expression and function of NFB family members.
|
Enrollment with follow-up
|
Natural History of Immunologic Deficiency Syndrome
Time Frame: Enrollment with follow-up
|
The objectives of the study are: (6) To perform whole genome, exome, or chemical analysis of genes in selected patients and family members to discover new primary immunodeficiency related genes.
Whole genome, exome, or other gene analysis will be done to determine which particular genetic variations can cause the various primary immunodeficiencies such as JAK3 deficiency or NEMO Syndrome.
We also seek to study whether particular variations are associated with more or less severe illness, or with specific types of symptoms, to understand the basic mechanism by which these altered genes cause cells to function differently, and to identify other genes causing SCID or NEMO-like syndrome.
In order to do this, we need blood specimens (or cells from inside the cheek) from patients and their families.
We will use these samples to identify which, if any, abnormality is present in the patient s genes, and to study the behavior of immune cells in vitro.
|
Enrollment with follow-up
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 990004
- 99-AR-0004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunologic Deficiency Syndrome
-
National Cancer Institute (NCI)CompletedLymphoma | Leukemia | Neoplasm | Immunologic Deficiency SyndromeUnited States
-
Grifols Therapeutics LLCCompletedImmunologic Deficiency SyndromeUnited States, Canada
-
Green Cross CorporationAtlantic Research GroupCompletedImmunologic Deficiency SyndromeUnited States, Canada
-
Charles University, Czech RepublicRecruitingSepsis | Immune Deficiency | Immunologic Paralysis | Immunologic SuppressionCzechia
-
Jongmin LeeCompletedSepsis | Immune DeficiencyKorea, Republic of
-
National Cancer Institute (NCI)CompletedLeukocyte Adhesion Deficiency SyndromeUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedLeukocyte Adhesion Deficiency SyndromeUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedLeukocyte-Adhesion Deficiency SyndromeUnited States
-
Makerere UniversityVaccine and Gene Therapy Institute, FloridaCompletedAcquired Immune Deficiency Syndrome Virus
-
Guang'anmen Hospital of China Academy of Chinese...UnknownHIV Infections | Acquired Immune Deficiency Syndrome VirusChina